GCM
KRRO icon

Graham Capital Management’s Korro Bio KRRO Stock Holding History

Graham Capital Management’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,766
Closed -$327K – 1355
2025
Q4 		$327K Buy
+40,766
New +$953K 0.01% 822

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Graham Capital Management's KRRO Position: Q1 2026 in Review

Graham Capital Management sold out of Korro Bio (KRRO) in Q1 2026, closing a stake of 40,766 shares — an estimated $327K sold.

Graham Capital Management first reported a position in KRRO in Q4 2025 and held it in 1 quarter. The position peaked at $327K in Q4 2025. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

  • Graham Capital Management reported no remaining Korro Bio position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 40,766 Korro Bio shares in Q1 2026, an estimated $327K.
  • Graham Capital Management first reported a position in Korro Bio in Q4 2025 and held it in 1 quarter.
  • Graham Capital Management's Korro Bio position peaked at $327K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.